The Board of Jubilant Life Sciences approved the financial results for the third quarter of the financial year 2012-13. In Q3 FY2013, income from operations was at Rs 1,306 crore growing over 19 per cent YoY. This was led by volume increase of 23 per cent. The earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at Rs 263 crore, up by 24 per cent YoY with EBITDA margins at 20.2 per cent, compared to 19.4 per cent last year.
The profit before exceptional items, tax and minority interest stood at Rs 146 crore, higher by 44 per cent YoY. The reported Profit after Tax grew 134 per cent at Rs 27 crore after considering the Rs 71 crore impact of exceptional items. Normalised PAT was higher at Rs 98 crore, up 27 per cent.
Shyam S Bhartia, Chairman and Managing Director and Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences said:, “Our strategy of enhancing presence in identified international markets is delivering results with 28 per cent growth and high 73 per cent contribution to revenue mix. We believe this momentum is sustainable due to strong product pipeline and order book position along with leveraging benefits from vertical integration.”
EP News Bureau – Mumbai
